U.S. markets close in 4 hours 19 minutes
  • S&P 500

    -18.64 (-0.49%)
  • Dow 30

    -55.51 (-0.18%)
  • Nasdaq

    -216.98 (-1.71%)
  • Russell 2000

    -56.70 (-2.64%)
  • Crude Oil

    +1.83 (+2.87%)
  • Gold

    -6.60 (-0.39%)
  • Silver

    -0.42 (-1.63%)

    -0.0059 (-0.49%)
  • 10-Yr Bond

    +0.0140 (+0.90%)

    -0.0083 (-0.60%)

    +0.2510 (+0.23%)

    -2,037.66 (-4.12%)
  • CMC Crypto 200

    +2.67 (+0.28%)
  • FTSE 100

    -7.88 (-0.12%)
  • Nikkei 225

    -65.79 (-0.23%)

Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Radius Health, Inc. RDUS announced that it has entered into an agreement with Paladin Labs Inc., an operating company of Endo International plc ENDP to register, commercialize and distribute abaloparatide in Canada.

Per the agreement, Paladin will in-license Radius’ abaloparatide subcutaneous injection, marketed as Tymlos, and abaloparatide transdermal device (abaloparatide-TD) in Canada. Radius will receive upfront and milestone payments up to $8 million from Paladin, wherein the latter will be responsible for all commercial activities related to abaloparatide in Canada. Radius is also eligible to receive tiered royalties up to the mid-twenties on net sales of the product in Canada.

Notably, Radius will supply the drug to Paladin, which will look after the registration distribution, sales, pricing and reimbursement activities related to abaloparatide in the given region.

We note that Tymlos’ subcutaneous injection is approved by the FDA for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Paladin is planning for a new drug submission for Tymlos to Health Canada by the first quarter of 2022. A potential approval in Canada will boost the drug’s sales.

Shares of Radius have declined 5.7% in the past year compared with the industry’s decrease of 3.4%.

price chart for RDUS
price chart for RDUS

We remind investors that the wearABLe phase III study is evaluating the safety and efficacy of abaloparatide-TD in the treatment of postmenopausal women with osteoporosis at high risk for fracture as compared with Tymlos.

We note that Tymlos sales are holding up pretty well, as the drug generated sales worth $148.5 million in the first nine months of 2020, reflecting an increase of 26.2% year over year. However, competition in the market remains stiff from bigwigs like Eli Lilly’s LLY Forteo and Amgen's AMGN Prolia.

Zacks Rank

Radius currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Endo International plc (ENDP) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Radius Health, Inc. (RDUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research